Asso Prof UCCOM I Kidneydoc | @UCKidney Lead, OncoNeph Program ❤️ Onconeph, 🏡 dialysis, ICU Neph Deputy Editor @KidneyNews Editorial Board @akdhjounal @BMCNephro ⭐️wars 🤓 Fav 🏞️ : Grand Tetons 🐶🐾🦴 Dad 🇮🇳 ~> 🇨🇦 ~> 🇺🇸https://bsky.app/profile/gudnephron.bsky.socialhttps://bsky.app/profile/gudnephron.bsky.social/post/3lfj3vnnqnk25https://www.nature.com/articles/s41581-024-00910-5?fromPaywallRec=false Can someone please share this article's PDF?12 Jan 2025 01:44 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lfj3vnnqnk25https://bsky.app/profile/gudnephron.bsky.social/post/3lcl55pvmr22qhttps://x.com/vincentrk/status/1864670480315158928?s=1205 Dec 2024 16:56 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lcl55pvmr22qhttps://bsky.app/profile/gudnephron.bsky.social/post/3lbnl2jyisk2chttps://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2823685 GLP-1 RAs may reduce the risk of cirrhosis progression and complications in patients with MASLD and DM, especially when started early. No benefit observed if initiated after cirrhosis onset. #LiverHealth #DiabetesCare #metabolicsyndrome23 Nov 2024 22:45 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lbnl2jyisk2chttps://bsky.app/profile/gudnephron.bsky.social/post/3lb72fd5djs2e#Nephsky #Medsky18 Nov 2024 04:09 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lb72fd5djs2ehttps://bsky.app/profile/gudnephron.bsky.social/post/3lb5k4ygks22lhttps://x.com/tony_breu/status/1857898510563049722?s=46&t=cdmHdjqTceX2ul4DwmNhTg Why iodine is used as IV contrast? Find this excellent Xorial by @tonybreu.bsky.social @zacharysmithmd.bsky.social @drjakenysather.bsky.social @jayminbpmd.bsky.social17 Nov 2024 13:46 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lb5k4ygks22lhttps://bsky.app/profile/gudnephron.bsky.social/post/3lb4gnvl3ek2lFrom X @ahascience.bsky.social #AHA2417 Nov 2024 03:11 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lb4gnvl3ek2lhttps://bsky.app/profile/gudnephron.bsky.social/post/3lb3z2jgjp22hhttps://www.linkedin.com/posts/prakash-gudsoorkar_tirzepatide-for-heart-failure-with-preserved-activity-7263688676428128257--Nb4?utm_source=combined_share_message&utm_medium=member_desktop_web #AHA24 #CVRM #CVoutcomes #Medsky #Cardiosky #Nephsky16 Nov 2024 23:07 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lb3z2jgjp22hhttps://bsky.app/profile/gudnephron.bsky.social/post/3lb35ncpydc2q#AHA24 @ahascience.bsky.social @ahajournals.bsky.social Folks attending AHA -what’s new in hypertension world? -what’s new is heart failure world? Whom to follow for updates?16 Nov 2024 14:57 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lb35ncpydc2qhttps://bsky.app/profile/gudnephron.bsky.social/post/3laztaixmak2qhttps://www.science.org/content/article/breakthrough-cancer-immunotherapy-now-taking-aim-autoimmune-disease16 Nov 2024 02:18 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3laztaixmak2qhttps://bsky.app/profile/gudnephron.bsky.social/post/3lazp2j2ltk2ehttps://www.nejm.org/doi/full/10.1056/NEJMoa2409712 👉Inebilizumab, a humanized, afucosylated IgG1 kappa monoclonal antibody specifically targets CD19 and results in rapid, deep, and durable B-cell depletion16 Nov 2024 01:03 +0000at://did:plc:a4gmcmpzk7oqapt4d7dnvsth/app.bsky.feed.post/3lazp2j2ltk2e